BioSpace News Archive

The investigational allogeneic CAR-T therapy P-BCMA-ALLO1 appears to be more effective following strong immunosuppressive preconditioning.

A CAR-T cell therapy for autoimmune diseases generated significant attention at the 2023 American Society of Hematology (ASH) annual meeting and Arcellx and Seagen posted promising data.

The company’s fiscal report for 2023 details revenue losses of $539 million and layoffs of 1,100 employees but notes that future GLP-1 manufacturing revenues could help stabilize its finances.

These factors, along with bluebird bio’s failure to receive a priority review voucher, all hurt the company’s stock price following Lyfgenia’s approval.

Patients treated with the investigational sickle cell therapy saw an increase in hemoglobin levels and improved red blood cell parameters.

The New York-based pharma reported at ASH that odronextamab had an 80% objective response rate, with 73% of patients experiencing a complete response.

The Indiana-based pharma shed shares after a study published Monday in JAMA showed “substantial” weight gain after patients discontinued treatment with the GLP-1 receptor agonist.

Vapotherm, Inc., announced its intention to voluntarily delist its common stock from The New York Stock Exchange and its filing of an application to have its common stock quoted on the OTCQX Marketplace.

Merck & Co. and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157).

Ascentage Pharma announced that it has released the latest efficacy and safety data of lisaftoclax, one of the company’s key drug candidates, in patients with heavily pretreated chronic lymphocytic leukemia, in a Poster Presentation at the 65th American Society of Hematology Annual Meeting, taking place in San Diego, CA, the United States.